Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The ...

Nov 20 (Reuters) - Moderna (MRNA.O), opens new tab said on Thursday it secured a five-year loan of $1.5 billion from Ares Management (ARES.N), opens new tab, as it targets up to 10% revenue growth ...

Moderna Inc. said it had secured a loan for up to $1.5 billion, a move aimed at shoring up the company’s finances as it struggles with the decline of its COVID business. The five-year loan facility ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Moderna has secured a major ...

Nov 19 (Reuters) - Moderna (MRNA.O), opens new tab said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the ...

With a $140 million investment, Moderna will bring its drug product manufacturing to the United States, joining a parade of drugmakers looking to strengthen their supply chains and reduce exposure to ...

Moderna (MRNA) announced on Wednesday that it has completed its domestic end-to-end mRNA manufacturing network with the onshoring of drug product manufacturing to its Moderna Technology Center in ...

Shares of Moderna, Inc. (NASDAQ: MRNA) are falling Thursday. The Massachusetts-based biotech company made two significant announcements regarding its finances and business strategy. What To Know: ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match the sales highs it experienced during the pandemic. Now, in an effort to ...

Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...

Ahead of its Analyst Day event on Thursday, Moderna (MRNA) indicated ~10% revenue growth for next year and increased its outlook for year-end liquidity, following up to a $1.5B loan from Ares ...

(Reuters) -Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management, as it targets up to 10% revenue growth next year. The vaccine maker, which is expected to unveil ...